Saturday, October 31, 2026

Canaan Stock Plummets 28% In Last 10 Sessions: Is It Time To Sell?

ViaNews Editorial Team

December 13, 2023

Canaan Stock Plummets 28% In Last 10 Sessions: Is It Time To Sell?

(VIANEWS) - Canaan (NASDAQ: CAN) shares have experienced a sharp drop over the course of 10 sessions. Over that timeframe, their price fell 28.49% from EUR1.72 on November 28th to EUR1.23 as of 21:47 EST Tuesday; this decline follows three straight sessions of losses. The NASDAQ index, however, is currently seeing an uptick of 0.084% to reach EUR14,443.93, marking three consecutive sessions of gains. Canaan's last closing price was EUR1.27 - 68.09% lower than its 52-week high of EUR3.98. Market fluctuations are inevitable and may be affected by numerous factors including economic indicators, company performance and global events. Investors should conduct comprehensive research before making investment decisions and seek professional advice before taking action.

About Canaan

Canaan Inc. of Singapore is a specialist provider in the design, research and sale of integrated circuit (IC) final mining equipment products used for bitcoin mining. Canaan also assembles and distributes mining equipment and spare parts across various locations including United States, Australia, Kazakhstan Hong Kong Canada Mainland China Thailand Sweden internationally. Established in 2013

Yearly Analysis

Based on this information, here is my investment outlook for Canaan stock: Canaan's stock is currently valued at EUR1.23, which is considerably below its 52-week low of EUR1.44. This may indicate that Canaan has underperformed and investors should carefully consider all aspects of financial performance as well as future prospects when making any investment decisions. Anticipated Sales Growth Canaan anticipates its sales growth to decline by an anticipated 68.4% this year; however, next year is projected at 12.5%; suggesting an improvement in performance going forward. Investors should carefully assess Canaan's ability to meet this projection and consider any impactful financial implications as a result. Canaan's EBITDA stands at 0.53 which may indicate its earnings are positive but relatively low. Investors should combine Canaan's EBITDA figure with other financial metrics such as revenue, net income and cash flow in order to gain an accurate picture of its financial health. Overall, Canaan may appear undervalued on paper; however, investors must carefully analyze its financial performance and prospects prior to making any investment decisions. Notably, negative sales growth was recorded this year and its ability to meet its growth projections for next year are crucial aspects to keep in mind before making investment decisions.

Technical Analysis

Stock Prices and Moving Averages an's stock prices have recently experienced difficulties, with its current value of EUR1.53 being significantly below both its 50-day moving average of EUR1.78 and 200-day moving average of EUR2.31. Canaan stock has been on an overall downward trend over the last several weeks and months. Trading Volume Is Updespite declining stock prices, trading volume for Canaan has increased; today's reported volume of 3735573 was 14.59% higher than its average volume of 3244570. Volatility and Stock Price ClassificationCanaan stock has recently experienced high volatility with average intraday variations ranging from 3.01%, 0.85% and 3.75% in recent weeks and months respectively. This could indicate renewed investor enthusiasm in their shares or even signal a change of trend for its decline.Volatility has remained elevated over the course of recent weeks and months; 3.01% for intraday variations over one week period alone was recorded last month, 1.85% and 3.75% during three month period of time respectively Canaan stock recently experienced its highest amplitude of average volatility for each week, month, and quarter over the past three months at 3.44% (week), 4.39% (month), and 3.75% (quarter). According to Canaan's stochastic oscillator indicator, Canaan's stock has recently become overbought (>=80), suggesting it may soon require correction. Overall OutlookWhile Canaan's share prices have been struggling, some encouraging signs have begun emerging. Rising trading volume and increased volatility could signal a potential turn in the stock's downward trend. Investors should exercise caution as the stock is currently considered overbought. To monitor its ongoing performance and any news or events which could influence its value, as well as to take an "observe and wait-and-see approach" before making any definitive decisions regarding it.

Quarter Analysis

Canaan's financial performance has witnessed a considerable drop in terms of sales growth and year-on-year revenue growth since their last quarterly reports were issued, with negative 38.5% sales growth for this quarter projected to improve to negative 20.3% in its next quarterly reports; growth estimates for both periods stand at 30.8% and 75%, respectively. Though sales growth may improve, it is critical to keep in mind the sharp decline in year-on-year quarterly revenue growth of 75.1% year over year over quarter, currently standing at 160.89M for twelve trailing months. Investors should proceed with caution when considering investing in Canaan due to its recent financial performance. Care should be taken when analyzing future growth potential and overall financial health before making investment decisions. In addition, investors should keep an eye out for any factors which may impede Canaan's performance such as industry trends, competitive landscape conditions and economic climate conditions that could influence Canaan.

Equity Analysis

Canaan currently has an EPS of EUR-0.47 for its last twelve month period, suggesting it is operating at a loss and should be approached with caution when investing in such companies. Canaan's return on equity over the last twelve months was negative -53.23%, suggesting it does not effectively utilize shareholder's equity to generate profits and should be taken into consideration when assessing financial performance and future growth potential of Canaan. Overall, investors should exercise extreme caution before considering an investment in Canaan due to its negative EPS and ROE figures. A thorough analysis of its financial statements, industry trends, and competitive landscape is advised before making any definitive investment decisions.

More news about Canaan (CAN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com